Company: BNRG
Filing Date: 2025-11-05
Form Type: F-3/A
Source: 0001213900-25-106675
Chunk: 9

Company: Brenmiller Energy Ltd.
Filing Date: 2025-11-05
Form: F-3/A
Chunk 9
---
20-F, incorporated by reference herein, and other information included or incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in our securities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Nasdaq Capital Market symbol:                      |     | “BNRG”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

The number of Ordinary Shares to be outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby are sold and is based on 3,859,800 Ordinary Shares outstanding as of November 5, 2025. This number excludes:

| ● | an aggregate of 103,805                                                                                                                   
 Ordinary Shares issuable upon the exercise of outstanding options to purchase Ordinary Shares, at exercise prices ranging between         
 $0.05 to $1,235.5 per Ordinary Share, issued to directors, officers, service providers and employees;                                     |
| ● | an aggregate of 3,489,795 Ordinary Shares issuable upon the exercise of outstanding warrants to                                           
 purchase Ordinary Shares, at exercise prices ranging between $2.09 to $83.3 per Ordinary Share, issued to certain investors in connection 
 with private placements and public offerings (including the Ordinary Shares issuable upon the exercise of Ordinary Warrants);             |
| ● | an aggregate of 1,660,839 Ordinary Shares issuable upon the conversion of 3,800 Preferred Shares,                                         
 with a conversion price of $2.288 per share; and                                                                                          |
| ● | the effect of the “full-ratchet” anti-dilution adjustment                                                                                 
 of the conversion price of our outstanding Preferred Shares and warrants.                                                                 |

<div align='center'>3

RISK FACTORS</div>

Investing in our securities involves risks. Please carefully consider the risk factors described below and those contained in our periodic reports filed with the Securities and Exchange Commission, or SEC, including those set forth under the caption “Summary Risk Factors” and “Item 3. Key Information – D. Risk Factors” in our 2024 Annual Report, which is incorporated by reference into this prospectus. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. You should be able to bear a complete loss of your investment.

<div align='center'>Risks Related to this Offering and Our Ordinary Shares</div>

There can be no assurance that we will be able to maintain the continued Nasdaq listing criteria.

On August 12,